News & Media

Recent updates from Arcutis.

November 21, 2022

Arcutis Biotherapeutics Publishes First Environmental, Social, and Governance (ESG) Report

November 17, 2022

Arcutis’ ZORYVE® (Roflumilast) Cream 0.3% Added to Express Scripts, Inc.® National Formularies in the United States

November 15, 2022

Arcutis Announces Positive Topline Results from INTEGUMENT-1 Pivotal Phase 3 Trial of Roflumilast Cream in Atopic Dermatitis in Adults and Children Aged Six Years and Older

November 11, 2022

Arcutis to Present at Upcoming Investor Conference

November 8, 2022

Arcutis Announces Third Quarter 2022 Financial Results and Provides Business Update

October 25, 2022

Arcutis to Report Third Quarter Financial Results

October 21, 2022

Nationwide Seborrheic Dermatitis Survey Shows Burdensome and Lengthy Path to Diagnosis

October 5, 2022

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 26, 2022

Arcutis Announces Positive Topline Results from ARRECTOR Pivotal Phase 3 Trial of Roflumilast Foam 0.3% in Scalp and Body Psoriasis

September 20, 2022

Journal of the American Medical Association Publishes Roflumilast Cream 0.3% Results from Pivotal DERMIS-1 and -2 Phase 3 Trials in Plaque Psoriasis

September 9, 2022

New Data from Arcutis’ STRATUM Pivotal Phase 3 Trial of Roflumilast Foam 0.3% in Seborrheic Dermatitis Presented at European Academy of Dermatology and Venereology (EADV) Congress

September 7, 2022

Arcutis Announces Acquisition of Ducentis BioTherapeutics Ltd.

Media Resources

Corporate Fact Sheet

Uncovering Psoriasis

Journal of the American Medical Association Roflumilast Cream 0.3% Result

Media Contact

Amanda Sheldon

805.418.5006
media@arcutis.com

Meaningful innovation at a glance.

Download our corporate fact sheet.

Download